ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Neurotoxic and some systemic effects of cadmium oxide nanoparticles following their subchronic intranasal administration to rats: experimental data analysis.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Industrial emissions of cadmium, which is used in various industries, and formation of cadmium nanoparticles during high-temperature technological processes aggravate the problem of chemical pollution. Insufficient understanding of the toxic impact of cadmium nanoparticles, coupled with the serious multisystem toxicity of this metal, necessitate expansion of knowledge about their potential toxic effects. We assessed the response of female outbred albino rats to subchronic exposure to cadmium oxide nanoparticles (CdO NPs) administered intranasally at the concentration of 0.5 mg/mL thrice a week during 6 weeks. Adverse changes in the exposed animals found at all levels of organization in the body, including ultrastructural damage, disruption of bioenergetic processes, altered cytological and weight indices, and behavioral responses, can be early signs of health disorders induced by CdO NPs, thus proving neurotoxic properties of the latter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.